Bio Products Laboratory Ltd.

6 articles with Bio Products Laboratory Ltd.

• Bio Products Laboratory Receives Triangle Business Journal's Fast 50 Award

  10/19/2020

  - Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies with US headquarters in Durham, North Carolina , and worldwide headquarters and manufacturing facilities in Elstree, UK, has been reco

• BPL Announces October 10th Hereditary Factor X Deficiency Awareness Day

  10/8/2020

  Bio Products Laboratory is proud to recognize the first Hereditary Factor X Deficiency Awareness Day on October 10th.

• FDA Accepts Supplemental Biologics License Application (BLA) and Grants Priority Review for Prophylactic and Pediatric Use for Bio Products Laboratory's Coagadex® (Coagulation Factor X, Human) for Treatment of Hereditary Factor X Deficiency

  5/23/2018

  Supplemental BLA based on clinical trial results from the Phase 3 TEN02 Study, a prospective study of Coagadex® for prophylaxis of bleeding episodes in children under 12 years old with moderate to severe hereditary factor X deficiency

• Bio Products Laboratory Presents New Phase III Data Demonstrating Prophylactic Coagadex (Coagulation Factor X, Human) Dosing Prevents Or Reduces Bleeding Episodes In Children With Moderate To Severe Hereditary Factor X Deficiency

  7/12/2017

• FDA Approves Bio Products Laboratory's Gammaplex 10% For Treatment Of Primary Immunodeficiency And Chronic Immune Thrombocytopenic Purpura

  2/7/2017

• Bio Products Laboratory Announces FDA Submission Of Biologics License Supplement For Gammaplex 10%

  4/13/2016